Quarterly report · Q3
4578.TEDINET S100S3PH
Period2023-01-01 → 2023-09-30
Filed2023-10-31
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.48T | 2023-01-01 → 2023-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥531.5bn | 2023-07-01 → 2023-09-30d | Cons. | Revenue IFRS |
| Revenue | ¥1.74T | 2022-01-01 → 2022-12-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥1.27T | 2022-01-01 → 2022-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥451.8bn | 2022-07-01 → 2022-09-30d | Cons. | Revenue IFRS |
| Operating income | ¥202.7bn | 2023-01-01 → 2023-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥72.0bn | 2023-07-01 → 2023-09-30d | Cons. | Operating profit loss IFRS |
| Operating income | ¥114.8bn | 2022-01-01 → 2022-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥47.7bn | 2022-07-01 → 2022-09-30d | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥213.2bn | 2023-01-01 → 2023-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥74.4bn | 2023-07-01 → 2023-09-30d | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥173.0bn | 2022-01-01 → 2022-12-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥146.0bn | 2022-01-01 → 2022-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥53.2bn | 2022-07-01 → 2022-09-30d | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥161.7bn | 2023-01-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥59.1bn | 2023-07-01 → 2023-09-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥133.9bn | 2022-01-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥111.0bn | 2022-01-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥41.3bn | 2022-07-01 → 2022-09-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥165.3bn | 2023-01-01 → 2023-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥60.3bn | 2023-07-01 → 2023-09-30d | Cons. | Profit loss IFRS |
| Net income | ¥114.0bn | 2022-01-01 → 2022-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥42.4bn | 2022-07-01 → 2022-09-30d | Cons. | Profit loss IFRS |
| Total assets | ¥3.42T | at 2023-09-30 | Cons. | Assets IFRS |
| Total assets | ¥3.10T | at 2022-12-31 | Cons. | Assets IFRS |
| Total assets | ¥3.19T | at 2022-09-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥892.2bn | at 2023-09-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥840.3bn | at 2022-12-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥2.53T | at 2023-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥2.26T | at 2022-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥2.33T | at 2022-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥2.05T | at 2021-12-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥2.48T | at 2023-09-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥2.23T | at 2022-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥2.30T | at 2022-09-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥518.6bn | at 2023-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥471.6bn | at 2022-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥477.3bn | at 2022-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥410.7bn | at 2021-12-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥186.0bn | 2023-01-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥211.8bn | 2022-01-01 → 2022-12-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥171.1bn | 2022-01-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥74.8bn | 2023-01-01 → 2023-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥81.6bn | 2022-01-01 → 2022-12-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥60.4bn | 2022-01-01 → 2022-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥82.4bn | 2023-01-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥95.5bn | 2022-01-01 → 2022-12-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥84.0bn | 2022-01-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥297.99 | 2023-01-01 → 2023-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥108.93 | 2023-07-01 → 2023-09-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥246.8 | 2022-01-01 → 2022-12-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥204.66 | 2022-01-01 → 2022-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥76.04 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥297.99 | 2023-01-01 → 2023-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥108.93 | 2023-07-01 → 2023-09-30d | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥246.78 | 2022-01-01 → 2022-12-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥204.64 | 2022-01-01 → 2022-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥76.02 | 2022-07-01 → 2022-09-30d | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 72.6% | at 2023-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 71.7% | at 2022-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 72.1% | at 2022-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 88
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-01-01 → 2023-09-30 | ¥131.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-07-01 → 2023-09-30 | ¥44.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-01-01 → 2023-09-30 | ¥99.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-07-01 → 2023-09-30 | ¥33.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-01-01 → 2023-09-30 | ¥32.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-07-01 → 2023-09-30 | ¥11.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-01-01 → 2023-09-30 | ¥9.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-07-01 → 2023-09-30 | ¥2.0bn |
| Reconciling Itemsreconciling | revenue | 2023-01-01 → 2023-09-30 | −¥32.9bn |
| Reconciling Itemsreconciling | revenue | 2023-07-01 → 2023-09-30 | −¥11.7bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-01-01 → 2023-09-30 | −¥32.9bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-07-01 → 2023-09-30 | −¥11.7bn |
| Reconciling Itemsreconciling | segment profit | 2023-01-01 → 2023-09-30 | −¥37.4bn |
| Reconciling Itemsreconciling | segment profit | 2023-07-01 → 2023-09-30 | −¥12.1bn |
| jpcrp040300-q3r_E21183-000Consumer Productsreportable segment | revenue | 2023-01-01 → 2023-09-30 | ¥28.5bn |
| jpcrp040300-q3r_E21183-000Consumer Productsreportable segment | revenue | 2023-07-01 → 2023-09-30 | ¥11.0bn |
| jpcrp040300-q3r_E21183-000Consumer Productsreportable segment | revenue external | 2023-01-01 → 2023-09-30 | ¥28.4bn |
| jpcrp040300-q3r_E21183-000Consumer Productsreportable segment | revenue external | 2023-07-01 → 2023-09-30 | ¥11.0bn |
| jpcrp040300-q3r_E21183-000Consumer Productsreportable segment | revenue intersegment | 2023-01-01 → 2023-09-30 | ¥12m |
| jpcrp040300-q3r_E21183-000Consumer Productsreportable segment | revenue intersegment | 2023-07-01 → 2023-09-30 | ¥3m |
| jpcrp040300-q3r_E21183-000Consumer Productsreportable segment | segment profit | 2023-01-01 → 2023-09-30 | ¥10.6bn |
| jpcrp040300-q3r_E21183-000Consumer Productsreportable segment | segment profit | 2023-07-01 → 2023-09-30 | ¥2.6bn |
| jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segment | revenue | 2023-01-01 → 2023-09-30 | ¥359.1bn |
| jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segment | revenue | 2023-07-01 → 2023-09-30 | ¥132.9bn |
| jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segment | revenue external | 2023-01-01 → 2023-09-30 | ¥359.0bn |
| jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segment | revenue external | 2023-07-01 → 2023-09-30 | ¥132.9bn |
| jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segment | revenue intersegment | 2023-01-01 → 2023-09-30 | ¥95m |
| jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segment | revenue intersegment | 2023-07-01 → 2023-09-30 | ¥40m |
| jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segment | segment profit | 2023-01-01 → 2023-09-30 | ¥28.3bn |
| jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segment | segment profit | 2023-07-01 → 2023-09-30 | ¥21.6bn |
| jpcrp040300-q3r_E21183-000Pharmaceuticalsreportable segment | revenue | 2023-01-01 → 2023-09-30 | ¥992.4bn |
| jpcrp040300-q3r_E21183-000Pharmaceuticalsreportable segment | revenue | 2023-07-01 → 2023-09-30 | ¥354.6bn |
| jpcrp040300-q3r_E21183-000Pharmaceuticalsreportable segment | revenue external | 2023-01-01 → 2023-09-30 | ¥992.4bn |
| jpcrp040300-q3r_E21183-000Pharmaceuticalsreportable segment | revenue external | 2023-07-01 → 2023-09-30 | ¥354.6bn |
| jpcrp040300-q3r_E21183-000Pharmaceuticalsreportable segment | segment profit | 2023-01-01 → 2023-09-30 | ¥191.5bn |
| jpcrp040300-q3r_E21183-000Pharmaceuticalsreportable segment | segment profit | 2023-07-01 → 2023-09-30 | ¥57.9bn |
| —segment total | revenue | 2023-01-01 → 2023-09-30 | ¥1.51T |
| —segment total | revenue | 2023-07-01 → 2023-09-30 | ¥543.3bn |
| —segment total | revenue external | 2023-01-01 → 2023-09-30 | ¥1.48T |
| —segment total | revenue external | 2023-07-01 → 2023-09-30 | ¥531.5bn |
| —segment total | revenue intersegment | 2023-01-01 → 2023-09-30 | ¥32.9bn |
| —segment total | revenue intersegment | 2023-07-01 → 2023-09-30 | ¥11.7bn |
| —segment total | segment profit | 2023-01-01 → 2023-09-30 | ¥240.1bn |
| —segment total | segment profit | 2023-07-01 → 2023-09-30 | ¥84.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-01-01 → 2022-09-30 | ¥126.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-07-01 → 2022-09-30 | ¥43.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-01-01 → 2022-09-30 | ¥94.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-07-01 → 2022-09-30 | ¥31.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-01-01 → 2022-09-30 | ¥31.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-07-01 → 2022-09-30 | ¥11.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-01-01 → 2022-09-30 | ¥9.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-07-01 → 2022-09-30 | ¥2.0bn |
| Reconciling Itemsreconciling | revenue | 2022-01-01 → 2022-09-30 | −¥32.0bn |
| Reconciling Itemsreconciling | revenue | 2022-07-01 → 2022-09-30 | −¥11.9bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-01-01 → 2022-09-30 | −¥32.0bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-07-01 → 2022-09-30 | −¥11.9bn |
| Reconciling Itemsreconciling | segment profit | 2022-01-01 → 2022-09-30 | −¥34.8bn |
| Reconciling Itemsreconciling | segment profit | 2022-07-01 → 2022-09-30 | −¥12.0bn |
| jpcrp040300-q3r_E21183-000Consumer Productsreportable segment | revenue | 2022-01-01 → 2022-09-30 | ¥27.0bn |
| jpcrp040300-q3r_E21183-000Consumer Productsreportable segment | revenue | 2022-07-01 → 2022-09-30 | ¥10.3bn |
| jpcrp040300-q3r_E21183-000Consumer Productsreportable segment | revenue external | 2022-01-01 → 2022-09-30 | ¥27.0bn |
| jpcrp040300-q3r_E21183-000Consumer Productsreportable segment | revenue external | 2022-07-01 → 2022-09-30 | ¥10.3bn |
| jpcrp040300-q3r_E21183-000Consumer Productsreportable segment | revenue intersegment | 2022-01-01 → 2022-09-30 | ¥18m |
| jpcrp040300-q3r_E21183-000Consumer Productsreportable segment | revenue intersegment | 2022-07-01 → 2022-09-30 | ¥12m |
| jpcrp040300-q3r_E21183-000Consumer Productsreportable segment | segment profit | 2022-01-01 → 2022-09-30 | ¥5.6bn |
| jpcrp040300-q3r_E21183-000Consumer Productsreportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥3.8bn |
| jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segment | revenue | 2022-01-01 → 2022-09-30 | ¥325.6bn |
| jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segment | revenue | 2022-07-01 → 2022-09-30 | ¥119.9bn |
| jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segment | revenue external | 2022-01-01 → 2022-09-30 | ¥325.6bn |
| jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segment | revenue external | 2022-07-01 → 2022-09-30 | ¥119.9bn |
| jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segment | revenue intersegment | 2022-01-01 → 2022-09-30 | ¥18m |
| jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segment | revenue intersegment | 2022-07-01 → 2022-09-30 | ¥7m |
| jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segment | segment profit | 2022-01-01 → 2022-09-30 | ¥49.8bn |
| jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥21.6bn |
| jpcrp040300-q3r_E21183-000Pharmaceuticalsreportable segment | revenue | 2022-01-01 → 2022-09-30 | ¥819.3bn |
| jpcrp040300-q3r_E21183-000Pharmaceuticalsreportable segment | revenue | 2022-07-01 → 2022-09-30 | ¥290.0bn |
| jpcrp040300-q3r_E21183-000Pharmaceuticalsreportable segment | revenue external | 2022-01-01 → 2022-09-30 | ¥819.3bn |
| jpcrp040300-q3r_E21183-000Pharmaceuticalsreportable segment | revenue external | 2022-07-01 → 2022-09-30 | ¥290.0bn |
| jpcrp040300-q3r_E21183-000Pharmaceuticalsreportable segment | segment profit | 2022-01-01 → 2022-09-30 | ¥84.5bn |
| jpcrp040300-q3r_E21183-000Pharmaceuticalsreportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥32.3bn |
| —segment total | revenue | 2022-01-01 → 2022-09-30 | ¥1.30T |
| —segment total | revenue | 2022-07-01 → 2022-09-30 | ¥463.7bn |
| —segment total | revenue external | 2022-01-01 → 2022-09-30 | ¥1.27T |
| —segment total | revenue external | 2022-07-01 → 2022-09-30 | ¥451.8bn |
| —segment total | revenue intersegment | 2022-01-01 → 2022-09-30 | ¥32.0bn |
| —segment total | revenue intersegment | 2022-07-01 → 2022-09-30 | ¥11.9bn |
| —segment total | segment profit | 2022-01-01 → 2022-09-30 | ¥149.7bn |
| —segment total | segment profit | 2022-07-01 → 2022-09-30 | ¥59.7bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 855
| Item | Context | Value | Unit |
|---|---|---|---|
| Cash and cash equivalents IFRS | CurrentQuarterInstant | 518639000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_jpcrp040300-q3r_E21183-000PharmaceuticalsReportableSegmentMember | 819334000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_jpcrp040300-q3r_E21183-000NutraceuticalsReportableSegmentMember | 325612000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_jpcrp040300-q3r_E21183-000ConsumerProductsReportableSegmentMember | 26987000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 94184000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_ReportableSegmentsMember | 1266119000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration | 1266119000000 | JPY |
| Intersegment revenue IFRS | Prior1YTDDuration_jpcrp040300-q3r_E21183-000PharmaceuticalsReportableSegmentMember | － | JPY |
| Intersegment revenue IFRS | Prior1YTDDuration_jpcrp040300-q3r_E21183-000NutraceuticalsReportableSegmentMember | 18000000 | JPY |
| Intersegment revenue IFRS | Prior1YTDDuration_jpcrp040300-q3r_E21183-000ConsumerProductsReportableSegmentMember | 18000000 | JPY |
| Intersegment revenue IFRS | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 31915000000 | JPY |
| Intersegment revenue IFRS | Prior1YTDDuration_ReportableSegmentsMember | 31952000000 | JPY |
| Intersegment revenue IFRS | Prior1YTDDuration_ReconcilingItemsMember | -31952000000 | JPY |
| Intersegment revenue IFRS | Prior1YTDDuration | － | JPY |
| Revenue IFRS | Prior1YTDDuration_jpcrp040300-q3r_E21183-000PharmaceuticalsReportableSegmentMember | 819334000000 | JPY |
| Revenue IFRS | Prior1YTDDuration_jpcrp040300-q3r_E21183-000NutraceuticalsReportableSegmentMember | 325631000000 | JPY |
| Revenue IFRS | Prior1YTDDuration_jpcrp040300-q3r_E21183-000ConsumerProductsReportableSegmentMember | 27006000000 | JPY |
| Revenue IFRS | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 126099000000 | JPY |
| Revenue IFRS | Prior1YTDDuration_ReportableSegmentsMember | 1298072000000 | JPY |
| Revenue IFRS | Prior1YTDDuration_ReconcilingItemsMember | -31952000000 | JPY |
| Revenue IFRS | Prior1YTDDuration | 1266119000000 | JPY |
| Operating profit loss IFRS | Prior1YTDDuration_jpcrp040300-q3r_E21183-000PharmaceuticalsReportableSegmentMember | 84472000000 | JPY |
| Operating profit loss IFRS | Prior1YTDDuration_jpcrp040300-q3r_E21183-000NutraceuticalsReportableSegmentMember | 49760000000 | JPY |
| Operating profit loss IFRS | Prior1YTDDuration_jpcrp040300-q3r_E21183-000ConsumerProductsReportableSegmentMember | 5596000000 | JPY |
| Operating profit loss IFRS | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 9855000000 | JPY |
| Operating profit loss IFRS | Prior1YTDDuration_ReportableSegmentsMember | 149684000000 | JPY |
| Operating profit loss IFRS | Prior1YTDDuration_ReconcilingItemsMember | -34835000000 | JPY |
| Operating profit loss IFRS | Prior1YTDDuration | 114848000000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_jpcrp040300-q3r_E21183-000PharmaceuticalsReportableSegmentMember | 992416000000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_jpcrp040300-q3r_E21183-000NutraceuticalsReportableSegmentMember | 359031000000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_jpcrp040300-q3r_E21183-000ConsumerProductsReportableSegmentMember | 28440000000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 99192000000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_ReportableSegmentsMember | 1479080000000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration | 1479080000000 | JPY |
| Intersegment revenue IFRS | CurrentYTDDuration_jpcrp040300-q3r_E21183-000PharmaceuticalsReportableSegmentMember | － | JPY |
| Intersegment revenue IFRS | CurrentYTDDuration_jpcrp040300-q3r_E21183-000NutraceuticalsReportableSegmentMember | 95000000 | JPY |
| Intersegment revenue IFRS | CurrentYTDDuration_jpcrp040300-q3r_E21183-000ConsumerProductsReportableSegmentMember | 12000000 | JPY |
| Intersegment revenue IFRS | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 32743000000 | JPY |
| Intersegment revenue IFRS | CurrentYTDDuration_ReportableSegmentsMember | 32851000000 | JPY |
| Intersegment revenue IFRS | CurrentYTDDuration_ReconcilingItemsMember | -32851000000 | JPY |
| Intersegment revenue IFRS | CurrentYTDDuration | － | JPY |
| Revenue IFRS | CurrentYTDDuration_jpcrp040300-q3r_E21183-000PharmaceuticalsReportableSegmentMember | 992416000000 | JPY |
| Revenue IFRS | CurrentYTDDuration_jpcrp040300-q3r_E21183-000NutraceuticalsReportableSegmentMember | 359126000000 | JPY |
| Revenue IFRS | CurrentYTDDuration_jpcrp040300-q3r_E21183-000ConsumerProductsReportableSegmentMember | 28453000000 | JPY |
| Revenue IFRS | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 131936000000 | JPY |
| Revenue IFRS | CurrentYTDDuration_ReportableSegmentsMember | 1511932000000 | JPY |
| Revenue IFRS | CurrentYTDDuration_ReconcilingItemsMember | -32851000000 | JPY |
| Revenue IFRS | CurrentYTDDuration | 1479080000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 16 of 16 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |